They say that every billionaire CEO dreams of their perfect, fairy-tale wedding. From an early age, infantile entrepreneurs born with a gleam in their eye and a knack for concocting brilliant business schemes wish for two things in life; that they accrue as much wealth as possible, and that one day, if possible, they can share that wealth with a significant other. When Jeff Bezos was born in the city that never sleeps, Albuquerque, New Mexico, he too fantasized about falling in love. “Maybe her name will be Alexa, no…that seems weird, but I’ll keep that one for safekeeping.”In 1992, a period heralded as the golden age of romance, Bezos met MacKenzie Tuttle, and within a year, they were married. Some say that Tuttle’s love for Bezos gave him the drive to found Amazon (AMZN) two years into their matrimony, while others praise his business acumen. Howbeit, as many single-and-ready-to-mingles will tell you, not all marriages can withstand the test of time.
It is with great sadness that I report that Bezos today announced, via a tweet from his Twitter account, that he and his wife are divorcing. Bezos’ tweet, sent out earlier morning, said:
“We want to make people aware of development in our lives. As our family and close friends know, after a long period of loving exploration and trial separation, we have decided to divorce and continue our shared lives as friends. We feel incredibly lucky to have found each other and deeply grateful for every one of the years we have been married to each other. If we had known we would separate after 25 years, we would do it all again…”
–Jeff Bezos via Twitter
As painful as this divorce must be for Bezos and his soon to be ex-wife, consumers, shareholders, and this content writer are concerned about how the divorce may impact one of the world’s most valuable publicly traded companies. For those unaware of divorce law in Washington State, the home of Jeff Bezos, the region has community property divorce laws, which may drastically harm Bezos’ wealth, given that his ex-wife may be entitled to half his assets. Reports suggest that nearly $137 billion is at stake in the coming months of the divorce.
In a 2013 Stanford study, entitled “Separation Anxiety: The Impact of CEO Divorce on Shareholders,” researchers investigated how companies and their chief executives fare over the course of divorce proceedings, ultimately arriving at the conclusion that there are “three potential ways in which a CEO divorce might impact a corporation and its shareholders.” The first, and perhaps most likely, relates to loss of control or influence. A CEO with a significant ownership stake in a company, like Bezos who owns 16.3%, may be forced to sell or transfer these assets to meet the demands of a divorce settlement. If this were to take place, not only would Bezos lose the influence he possesses over Amazon (AMZN), but due to such a large sell of, the company’s share value could drop as a result. The report says that “shareholder reaction to the loss of control will; vary, depending on the view that investors have of CEO performance and governance quality.” The second potential outcome suggests that a virile can affect the productivity, concentration, and energy levels of the CEO. According to Wheatley, Vogt, and Murrell, “Thirty-seven percent of companies report that employee divorce negatively impacts firm productivity, sometimes leading to premature retirement in extreme cases. Presently, Amazon’s (AMZN) shares have remained largely uninjured, up 0.41% in late-afternoon trading on Wednesday, with shares at $1,663.64 per share. Analysts believe Amazon (AMZN) stock is safe, for now, because of how Bezos worded the divorce in his tweet, stressing that he and his wife would remain friends.
Acadia (ACAD) Stock Price is up 60% This Month; Bullish Signal For Biotechs?
One sector that has always been a favorite of investors of all varieties is the pharmaceutical sector and all investors like a turnaround story. Over the years, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had been one of the better-known strugglers in the industry. That was reflected in the stock price as well. But recent developments have breathed new life in the stock, which could be an indicator for the biotech industry at large.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
There has been no lack of attention on biotech penny stocks this year. At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes.
The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods. For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.
On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.
Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.
Acadia (ACAD) Stock Price: Important Developments
People who had held on to the stock through the barren years got a nice boost recently. This came after Acadia’s well-known medicine Nuplazid recorded better than expected sales. In addition to that, there were encouraging results from a dementia-driven psychosis study. Hence, it is important to figure out whether it is perhaps time to buy the stock.
While the signs are no doubt encouraging, it is important to note that data reveals that around 60,000 people in the United States are diagnosed with Parkinson’s every year. Out of those, a large proportion (50% to 80%) suffers from dementia. Hence it can be argued that the market is simply not too big for Acadia’s Nuplazid.
Moreover, different types of dementia are brought on by Alzheimer’s disease, which is why all of it might not actually fall into Acadia’s lap. That being said, it is also well known that antipsychotic drugs have only been approved for the treatment of Parkinson’s and hence the Alzheimer’s market is already out of the question.
Projections suggest that the sale of Nuplazid could grow to more than $1 billion in 2023 from $224 million in 2018. While that is encouraging, it is also important to note that the growth has been priced into the Acadia stock price.
However, if Acadia’s plans for growth somehow run into any trouble, then there is every chance of the stock price plummeting once again. The company is recovering and there is some time before the patient population for Nuplazid can be expanded sufficiently. In the meantime, investors need to be a bit more patient.
Shares of ACAD are up over 60% over the past week and made a new multi-year high of $43.98.
Advanced Micro Devices (AMD) Stock Price Consolidates After the Recent Rally: What Next?
It sometimes so happens that the price action and activity around a stock reaches a decisive stage, from which it can go only one way or another. In other words, it is the moment when the future of a stock is a straight shootout between the bulls and the bears.
The Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has now reached such a stage according to keen observers and hence the stock is now trading within a very narrow range as the squeeze continues. In such a situation, it is only natural for investors to wonder which way this whole thing is going to go in the short term.
First and foremost, it is important to point out that since Lisa Su took over as the Chief Executive Officer in 2014, AMD has managed to stage a remarkable turnaround. Although the process has been slow, it proved to be highly lucrative for those investors who were patient. The stock has risen steadily over the past three years and rallied from $2 to around $30.
However, at the time, the investors had backed the company’s turnaround but now the story has changed and the turnaround has concluded. The bulls seem to think that the run is going to continue while bears believe that with the conclusion of the turnaround, the stock is all set to fall.
After all, if there is no further upside, then there is no point in holding the stock. This has caused uncertainty in the stock and its price action. Analysts believe that while the turnaround story had resulted in enormous gains for many investors, the stock is now expected to mirror the performance of the broader market. This factor lays credence to the bears’ position and moreover, the small matter of a looming Presidential election needs to be considered as well. Markets are generally flat in the lead-up and hence, analysts believe that although AMD might continue to be range-bound, it is unlikely that it is going to go on a rally.
Stock Price Newsletter – September 18, 2019
4 Penny Stocks Catching Attention This Week
Several economic and sector events have sparked interest in a number of small-cap and micro-cap stocks this week.
Airline Stocks In Focus; Spur Interest In Detection Tech Companies?
The latest mix of attacks and focus on airlines could have a different impact on sectors like weapons detection & defense. What could this mean for stocks to watch this week?
Top Biotech Stocks To Watch This Week
The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology1 week ago
This Biotech Stock Could Hold the Key to a Multi-Billion Dollar Market Shake-up
Biotechnology2 weeks ago
Tiziana Life Sciences (TLSA) Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
Biotechnology1 week ago
Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key
Featured3 days ago
Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
Featured1 week ago
This Biotech Stock is Looking to Deliver Huge Positive Change
Featured3 days ago
Top 4 Penny Stocks To Watch This Week
Biotechnology1 week ago
Are Biotech Stocks Setting The Stage For Another Bull Trend?
Biotechnology1 week ago
Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers